Drugs.com Clinical Trial ResultsOriginal article
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
Data ReadoutpositiveCRB-913Positive
AI Analysis
Summary
Corbus Pharmaceuticals announced positive topline data from the CANYON-1 study of daily oral CRB-913 for obesity treatment. The positive results represent a significant clinical milestone for the company's obesity program.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Positive topline data from CANYON-1 study
Importance:7/10
Sentiment:
0.80
obesityCRB-913CANYON-1topline dataoral therapy
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 14, 2026 7:09 PM